Press Release - Remedium Lifecare Announces ?49.19 Cr Rights Issue for Expansion
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Ltd has received BSE approval for a rights issue worth ₹49.19 crore to fund its growth plans. Existing shareholders as on the record date of April 15, 2025 will be offered 61 new equity shares for every 50 shares held, at a price of ₹1 per share (face value ₹1). The total issue, if fully subscribed, will result in 49.19 crore new equity shares being issued. The company plans to use the funds for working capital needs, R&D equipment, and manufacturing expansion. The announcement comes alongside a recent ₹182.7 crore multi-year export contract with a UK-based pharmaceutical distributor signed in February 2025.
Existing shareholders will see partial dilution but get a chance to maintain their stake by participating before the April 15 record date. The low issue price and aggressive 61:50 ratio make subscription attractive, while the capital raise supports the company's expansion and recent export wins.